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Class II α-isoform of phosphatidylinositol 3-kinases (PI3K-C2α) is localized in 
endosomes, the trans-Golgi network and clathrin-coated vesicles, however, its 
functional role is little understood. Global or endothelial cell (EC)-specific 
targeted disruption of PI3K-C2α resulted in embryonic lethality due to defects in 
sprouting angiogenesis and vascular maturation. PI3K-C2α knockdown in ECs 
induced decreased phospatidylinositol 3-phosphate-enriched endosomes, 
impaired endosomal trafficking, and defective delivery of VE-cadherin to EC 
junctions and its assembly. PI3K-C2α knockdown also impeded cell signaling 
including vascular endothelial growth factor receptor internalization and 
endosomal RhoA activation. These together led to defective EC migration, 
proliferation, tube formation and barrier integrity. Endothelial PI3K-C2α deletion 
suppressed post-ischemic and tumor angiogenesis, and diminished vascular 
barrier function, with greatly augmented susceptibility to anaphylaxis and a 
higher incidence of dissecting aortic aneurysm formation in response to 
angiotensin II infusion. Thus, PI3K-C2α plays a crucial role in vascular formation 




Formation of the vascular network by vasculogenesis and angiogenesis is essential for 
embryonic development, repair and remodeling of tissues in adults, as well as tumor 
growth. The angiogenic response to vascular endothelial growth factor (VEGF) and other 
factors begins with vascular leakage and dissolution of the subendothelial basement 
membrane, followed by proliferation and migration of vascular EC1,2. Then, formation of 
the intercellular junctions results in initial sprouts from existing vessels. The newly 
formed endothelial tubes are associated with mural cells, i.e. smooth muscle cells (SMC) 
and pericytes, thus becoming mature and stabilized3. Tightness of the intercellular 
junctions, particularly adherens junctions composed of VE-cadherin, controls vascular 
permeability4,5. Quiescent, stabilized vasculature with intact barrier integrity dominates in 
the healthy condition. In contrast, in pathological conditions, such as tumors, the 
vasculature is generally inmaturate and leaky. In the case of vascular insult such as 
excessive angiotensin II (Ang II) activity, increased vascular permeability is asssociated 
with leukocyte infiltration in the vascular wall and vascular disruption6,7. Therefore, 
stabilization of the vasculature and maintenance of vascular integrity is essential for 
vascular and tissue homeostasis8,9. 
 PI3Ks are an enzyme family that phosphorylates membrane inositol lipids at 
the 3’ position of the inositol ring. The lipid products of PI3Ks serve as important 
intracellular messengers by interacting with effector proteins, which include protein 
kinases, guanine nucleotide exchangers for G proteins, and actin cytoskeleton-regulating 
proteins. Through these actions, PI3Ks regulate a diverse array of cellular processes10-12. 
PI3Ks comprise three classes. Class I PI3Ks, which are activated by tyrosine kinases and 
G protein-coupled receptors, consist of four catalytic subunits: p110α, p110β, p110γ and 
p110δ, and mainly produce phosphatidylinositol (PtdIns) 3,4,5-trisphosphates 
(PtdIns(3,4,5)P3). Class I PI3Ks, especially p110α, in EC are indispensable for 
angiogenesis in the early embryo by regulating EC proliferation, migration and 
morphogenesis13,14. Class III has a single member, Vps34, which generates PtdIns(3)P to 
regulate vesicular trafficking15. In contrast to class I and III, the physiological functions 
of class II PI3Ks are little understood. Class II PI3Ks comprise three members, PI3K-
C2α (C2α), PI3K-C2β (C2β) and PI3K-C2γ (C2γ), and mainly produce PtdIns(3)P in 
vivo16,17. Among the three class II PI3Ks, C2α is distinct from C2β, C2γ and other PI3K 
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members in that it has unique structures including a clathrin-binding site in the N-
terminal stretch and relative resistance to PI3K inhibitors16,18. C2α is expressed in 
selected cell populations including epithelium, vascular endothelium, and smooth 
muscle19,20. C2α is enriched in clathrin-coated endocytic vesicles, other endosomes and 
the trans-Golgi network (TGN), and is suggested to regulate intracellular vesicular 
trafficking16,18,21,22. In vitro studies21,23,24 showed that various extracellular stimuli 
including cytokines, insulin and integrin ligation modestly stimulated C2α. However, the 
in vivo function of C2α is largely unknown, although a recent study25 showed that a 
hypomorphic C2α mutant allele resulted in impairment of renal glomerular formation. 
 By utilizing a gene-targeting strategy, we explored the in vivo role of C2α. We 
found that C2α plays a crucial role in developmental and pathological angiogenesis in an 
EC-autonomous manner. Notably, the angiogenic effect of C2α is mediated through 
mechanisms distinct from those of class I PI3Ks: C2α primarily regulates vesicular 
trafficking, which is essential for normal delivery of membrane proteins including VE-
cadherin and particular cellular signaling, thus playing a pivotal role in EC proliferaton, 
survival, migration, morphogenesis, and thereby angiogenesis. The second crucial role of 
C2α in the vasculature is to manintain endothelial barrier function and to protect the 





Endothelial C2α is crucial for developmental and postnatal physiological 
angiogenesis and vascular maturation 
Homozygous global C2α-deleted mutant (Pik3c2a–/–) embryos were growth-retarded 
from embryonic day 8.5 (E8.5) and died around E10.5–E11.5 due to defects in vascular 
formation (Fig. 1, Supplementary Table 1 and Supplementary Figs. 1–3), suggesting 
an essential non-redundant role of class II PI3Ks in murine development. Whole-mount 
CD31 staining of embryos revealed severe defects in vascular development throughout 
the embryonic body (Fig. 1a). In contrast to wild-type (Pik3c2a+/+) embryos, the major 
vessels including the dorsal aorta, intersomitic vessels, and branchial arches were 
severely disorganized or absent in Pik3c2a–/–  embryos (arrowheads in Fig. 1a (bottom)). 
Smooth muscle α-actin (αSMA)-positive mural cells were barely detected in the 
Pik3c2a–/–  dorsal aorta, but readily detected in heart of Pik3c2a–/–  as well as wild-type 
embryos (Fig. 1b). In support of the above data, C2α was highly expressed in vascular 
EC at the mid-gestation among other cell types including SMC, cardiomyocytes (CM), 
and gastrointestinal epithelium (Supplementary Fig. 4). 
To determine the cell type(s) responsible for the phenotype in Pik3c2a–/– embryos, 
three cardiovascular-specific C2α deletion mutants were generated (Supplementary Fig. 
5). Both SMC-specific (Pik3c2aflox/flox;SM22αCre = Pik3c2aΔSMC) and CM-specific 
(Pik3c2aflox/flox;Nkx2-5Cre26= Pik3c2aΔCM) C2α-deletion mutants developed normally, 
and were born with the expected Mendelian ratio (Supplementary Tables 2 & 3). 
However, EC-specific C2α-deletion mutants (Pik3c2aflox/flox;Tie2Cre27= Pik3c2aΔEC) 
were embryonic lethal (Supplementary Tables 3–7) due to multi-organ abnormalities 
including severely impaired vascular formation, indicating that endothelial C2α is 
essential for normal vascular formation and development. The most severely affected 
Pik3c2aΔEC mutants died at E12.5 and phenocopied a global Pik3c2a-null embryo. 
Pik3c2aΔEC embryos displayed marked dilation of subcutaneous microvessels, with 
hemorrhage (Fig. 1c (bottom)). Double immunofluorescent staining using CD31- and 
αSMA-specific antibodies of Pik3c2aΔEC embryo tissue showed decreases in vascular 
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branching and EC-covered area (31% and 36% reduction, respectively, compared with 
control embryos. P < 0.05, Fig. 1c,d), and discontinuous and incomplete coverage of 
microvessels with vascular SMC (Fig. 1c and Supplementary Fig. 6 a,b). 
Immunostaining using VE-cadherin- and NG2-specific antibodies revealed that the 
capillaries had discontinuous adherens junction formation and poor coverage with NG2-
positive pericytes, which were frequently rounded with cellular processes detached from 
the capillary wall (Fig. 1c and Supplementary Fig. 6c). In Pik3c2aΔEC;Rosa26R 
embryos, β-galactosidase (βGal)-positive but CD31-negative cord-like cell clusters were 
interspersed within capillaries (Fig. 1e (bottom)). Taken together, these results imply that 
loss of C2α expression in EC is responsible for the phenotype observed in Pik3c2a–/– 
mice. 
Since Pik3c2aΔEC (Pik3c2aflox/flox;Tie2Cre) mice are embryonic lethal, we created 
tamoxifen-inducible, conditional EC-specific C2α-deletion mice (Pik3c2aiΔEC) which 
express tamoxifen-activated Cre recombinase under the VE-cadherin promotor28 
(Pik3c2aflox/flox;Cdh5(PAC)-CreERT2, Supplementary Fig. 5e) and studied the role of 
C2α in postnatal physiological angiogenesis, using a retinal angiogenesis model. 
Administration of tamoxifen at 3 days after birth (P3) resulted in a marked reduction in 
C2α protein expression at P6 in EC isolated from the lung but not in SMC (Fig. 2a). In 
the retina of mice at P6, EC-specific C2α inactivation induced by tamoxifen 
administration markedly inhibited retinal angiogenesis: the vessel area, the tip cell 
number and the filopodial number at the vascularizing front was reduced by 46%, 32%, 
and 48%, respectively, in the superficial layer of the retina in Pik3c2aiΔEC mice compared 
with control mice (Fig. 2b and Supplementary Fig. 7). Perpendicular sprouting and 
horizontal network formation in the deeper retina were also severely impaired in the 
Pik3c2aiΔEC retina (Fig. 2c). In the retina of Pik3c2aΔEC mice, a marked increase (5.5-fold 
increase) in apoptosis was observed compared with that in control littermates (P < 0.01, 
Fig. 2b (right)). EC-specific hemizygously C2α-deleted (Pik3c2aflox/+;Tie2Cre) mice also 
showed decreased retinal angiogenesis with reduced tip cells and filopodia at the 




C2α is involved in endothelial migration, proliferation and tube-formation 
through mechanisms involving RhoA regulation 
Knockdown of either p110α or C2α in human umbilical vein EC (HUVEC) by specific 
short interfering RNAs (siRNAs), but not by scrambled (sc), C2β-, Vps34-, or p110β-
specific siRNAs, inhibited VEGF-A-induced capillary-like tube formation (Fig. 3a and 
Supplementary Fig. 9a,b). In complete growth medium with serum and growth factor 
supplements (EBM2TM), knockdown of C2α still inhibited tube formation whereas 
knockdown of p110α or other PI3Ks was ineffective; knockdown of both p110α and 
p110β inhibited tube formation in EBM2 (Supplementary Fig. 9c).  
C2α knockdown also markedly inhibited transwell migration of HUVEC toward 
VEGF-A (P < 0.001, Fig. 3b) but not of SMC toward PDGF-BB, augmented apoptosis of 
HUVEC (Supplementary Fig. 9d,e) and modestly inhibited serum-induced proliferation 
(Supplementary Fig. 9f). In contrast, C2α deletion had no effect on proliferation of 
SMCs (Supplementary Fig. 9g,h). These results indicate C2α-specific, essential roles in 
EC activities. 
C2α silencing did not alter VEGF-A-induced phosphorylation of VEGF receptor 2 
(VEGFR2), p42/p44 ERK, Akt, endothelial NOS (eNOS), or p21-activated kinase-2 
(PAK2) (Fig. 3c), which differed from the effects of p110α knockdown10-13. However, 
C2α knockdown markedly inhibited VEGF-A-induced phosphorylation of MYPT1, a 
substrate of Rho kinase (Fig. 3c,d), and RhoA activation (Fig. 3e,f). Consistent with this, 
immunostaining using an antibody that specifically recognizes the GTP-bound active 
form of RhoA (Supplementary Fig. 10a) showed that knockdown of either C2α or 
p110α suppressed VEGF-A-induced RhoA activation (Supplementary Fig. 10b). 
Knockdown of C2α but not of p110α or Vps34 inhibited serum/growth factor 
supplements-induced RhoA activation (Supplementary Fig. 10c). C2α knockdown also 
reduced VEGF-A-induced Rac1 and FGF2-induced Rap1 activation (Supplementary 
Fig. 11), which participate in stabilizing VE-cadherin at EC-EC contacts5,29.  
RhoA knockdown, as well as VE-cadherin knockdown, abolished VEGF-A-induced 
tube formation (P < 0.01, Supplementary Fig. 12a,b). In a mixed culture of dominant 
negative RhoA mutant RhoAN19-expressing HUVEC and control HUVEC, RhoAN19-
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expressing HUVEC showed rounded cells that failed to form cell-cell contacts through 
cell protrusions as seen in normal HUVEC (Supplementary Fig. 12c,d (red arrowheads 
in right panel). These observations together suggest that C2α plays an essential role for 
morphogenesis through the mechanisms involving RhoA. 
 
C2α is required for endosomal trafficking, which is crucial for Rho-
dependent VE-cadherin delivery and assembly 
In sc-siRNA-treated control HUVEC that were transfected with the PtdIns(3)P-specific 
probe mRFP-tagged 2×FYVE domain30,31, the mRFP-2×FYVE signal was mainly 
localized in endosomes (Fig. 4a). C2α depletion markedly reduced the number of mRFP-
2×FYVE+-vesicles (P < 0.01), whereas PI3K p110α- or Vps34-depletion did not alter the 
number of mRFP-2×FYVE+-vesicles. Total cellular content of PtdIns(3)P, but not 
PtdIns(3,4)P2, PtdIns(3,5)P2 and PtdIns(3,4,5)P3, in C2α-deleted cells was reduced 
compared with that in control cells (Supplementary Fig. 13). Thus, C2α has a significant 
contribution to PtdIns(3)P accumulation in the endosomal compartment. Consistent with 
this, C2α was detected in a granular pattern in HUVEC with enrichment in the 
perinuclear region, and partially co-localized with markers of clathrin-coated vesicles, 
TGN and early endosomes (Supplementary Fig. 14a–c)16,18,22.  GFP-C2α also 
substantially overlapped with mRFP-2×FYVE (Supplementary Fig. 15a and Movie 1). 
The motility, fusion and fission  of GFP-2×FYVE+-vesicles were markedly attenuated in 
C2α-depleted cells (Supplementary Movies 2 & 3), suggesting that C2α is involved in 
endosomal trafficking. Knockdown of C2α, but not of p110α or Vps34, caused 
enlargement of the Golgi/TGN area (Supplementary Fig. 14d). Swelling of the 
Golgi/TGN compartment was also demonstrated in EC of the Pik3c2a–/– dorsal aorta by 
electron microscopy (Supplementary Fig. 14e). 
In C2α-depleted, but not p110α- or Vps34-depleted, EC, the trafficking of VE-
cadherin between the TGN and the intercellular junctions at the plasma membrane was 
disrupted (Fig. 4b and Supplementary Movies 4 & 5). C2α was partially co-localized 
with VE-cadherin in the Golgi/TGN and endosomes but not in the intercellular junction 
(Supplementary Fig. 15b). A portion of mRFP-2×FYVE+-vesicles were positive for VE-
cadherin-GFP, suggesting the transport of VE-cadherin by PtdIns(3)P+-vesicles 
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(Supplementary Fig. 15c). In agreement with these findings, the accumulation of VE-
cadherin at the cell-cell contacts in C2α-depleted, but not p110α- or Vps34-depleted, 
HUVEC was reduced and discontinuous, with reduced β-catenin association and 
intracellular instability of VE-cadherin protein compared with that in control HUVEC 
(Fig. 4c and Supplementary Fig. 16a,b). Expression of RhoAN19 impaired VE-cadherin 
trafficking between the TGN and the plasma membrane, thereby resulting in disturbed 
VE-cadherin clustering at cell-cell contacts (Fig. 4b (bottom), Supplementary Movie 6, 
and Supplementary Fig. 16c). In mixed cultures of normal HUVEC and RhoA-depleted 
HUVEC, VE-cadherin clustering was impaired at the boundary between RhoA-depleted 
cells (Supplementary Fig. 16d). In C2α-depleted HUVEC, the expression of the 
constitutively active RhoA mutant GFP-RhoAV14 but not of GFP-wild-type RhoA 
partially restored defective VE-cadherin clustering at the cell-cell contacts (arrowheads 
in Supplementary Fig. 16e), whereas in sc-siRNA-treated control HUVEC the 
expression of  GFP-RhoAN19 but not of GFP-wild-type RhoA attenuated VE-cadherin 
assembly. 
Because C2α is necessary for endosomal trafficking and endosomes are now 
recognized to be involved in the activation of signaling molecules including Rho 
GTPases32, we explored how C2α regulates RhoA activation in cells by adopting a 
fluorescence resonance energy transfer (FRET) imaging technique. RhoA was activated 
in both the intracellular vesicular compartment and the plasma membrane, with intense 
signals at cell-cell contacts in HUVEC (Fig. 4d, Supplementary Movie 7). A substantial 
portion of the intracellular FRET signal coincided with 2×FYVE signals (Fig. 4e). C2α 
knockdown inhibited the RhoA-FRET signal in both the endosomes and the plasma 
membrane (Fig. 4d–g, Supplementary Movie 8), indicating that C2α is necessary for 
RhoA activation in PtdIns(3)P-enriched endosomes and the plasma membrane. We 
further studied the role of C2α in VEGF receptor internalization, which could be an event 
upstream of RhoA activation. VEGF-A stimulated the internalization of VEGFR2 into 
the 2×FYVE+-vesicular compartment (Fig. 4h, left), which was dampened by C2α 
depletion (Fig. 4h, right). VEGF-A stimulation induced phosphorylation of VEGFR2 at 
the plasma membrane in HUVEC at 2 min, and most phosphorylated VEGFR2 was re-
distributed in the intracellular compartment, mainly in EEA1+-endosomes, at 30 min 
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(Supplementary Fig. 17 (upper)). C2α depletion did not inhibit the initial VEGFR2 
phosphorylation in the plasma membrane at the early time point but inhibited the 
internalization of  phosphorylated VEGFR2 (Supplementary Fig. 17 (lower)). 
Furthermore, dynasore, an inhibitor of dynamin-dependent endocytosis33, inhibited 
growth factor-induced RhoA activation, VE-cadherin assembly and tube formation 
(Supplementary Fig. 18a–d). Thus, C2α is indispensable for internalization of activated 
receptors, activation of RhoA and other signaling molecules on endosomes, RhoA-
dependent trafficking and assembly of VE-cadherin, and endothelial morphogenesis. 
 
Endothelial C2α is essential for post-ischemic and tumor angiogenesis 
We studied the role of endothelial C2α in pathological angiogenesis using post-ischemic 
and tumor angiogenesis models. In Pik3c2aiΔEC mice, the recovery of blood flow in the 
ischemic hindlimb after surgical femoral arteriectomy was suppressed during the 
postoperative days 14–28 compared with that in control Pik3c2aflox/flox mice (P < 0.0001 
on day 28, Fig. 5a). Immunofluorescent staining using CD31-specific antibody showed 
an approximately 50% decrease in microvessels in ischemic muscle of Pik3c2aiΔEC mice 
on postoperative day 28 (P < 0.0001, Fig. 5b). Pik3c2aiΔEC mice exhibited diminished 
tumor volumes and weight of implanted Lewis lung carcinoma (LLC) and B16-BL6 
melanoma tumor compared with control Pik3c2aflox/flox mice (P < 0.01, Fig. 5c). 
Immunofluorescent staining using CD31-specific antibody showed that the microvessel 
density in LLC tumors was reduced in Pik3c2aiΔEC mice compared with that in control 
mice (P < 0.05, Fig. 5d). Moreover, double-immunostaining with CD31- and NG2-
specific antibodies revealed that the tumor microvessels in Pik3c2aiΔEC mice had poor 
coverage with NG2+-pericytes, which were frequently rounded or detached from the 
microvessels (Fig. 5e). 
 
C2α is required for vascular barrier function and integrity 
The permeability of a monolayer of C2α-depleted HUVEC was increased under both 
resting and VEGF-A-stimulated conditions compared with that of control HUVEC (P < 
0.05, Fig. 6a). VEGF-A induced a greater increase in leakage of intravenously 
administered Evans blue dye in the skin of Pik3c2a+/– mice (P < 0.05, Fig. 6b). We 
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studied the vascular responses to hyperpermeability- and inflammation-eliciting insults in 
global Pik3c2a+/– and wild-type mice. Intravenous (i.v.) injection of a low-dose of 
platelet-activating factor (PAF), a mediator of anaphylactic shock34, did not affect 
survival in wild-type mice whereas it induced death in all Pik3c2a+/– littermates within 40 
min with increases in hematocrit and Evans blue leakage in the lung (Fig. 6c,d). A higher 
dose of PAF, which induced death only in a portion (about 30%) of wild-type mice, 
caused more rapid death of all Pik3c2a+/– mice. PAF-induced increases in plasma 
histamine and IL-4, anaphylactic mediators, were similar in wild-type and C2α+/– mice 
(Supplementary Fig. 19), suggesting that C2α deficiency primarily impairs endothelial 
function, resulting in vascular barrier disruption. 
In Pik3c2a+/– mice, chronic Ang II infusion induced more robust hyperpermeability in 
the aorta and coronary vessels compared with that in wild-type littermates (Fig. 6e). En 
face immunostaining using VE-cadherin-specific antibody of the aorta showed 
disorganization of adherens junctions in Pik3c2a+/– mice given Ang II (Fig. 6f). 
Concomitantly, a higher incidence of aortic aneurysms with dissection, resultant rupture 
and death was observed in Pik3c2a+/– mice compared with wild-type littermates 
(aneurysm occurrence; 23/48 Pik3c2a+/– mice vs. 5/44 wild-type mice) (P < 0.01, Fig. 6g 
& h). Conditional EC-specific deletion of C2α also resulted in a higher occurrence of 
dissecting aneurysms compared with control mice (aneurysm occurrence; 5/20 
Pik3c2aiΔEC mice vs. 1/13 control mice) (P < 0.01, Fig. 6g). There was no difference in 
blood pressure between Pik3c2a-deleted and control mice (data not shown). Thus, the 
aortic wall of C2α-deficient mice seems to be fragile compared with that of WT mice. 
AngII infusion stimulated MMP-2 and MMP-9 activities, which are implicated in the 
formation of aneurysms6,7,35,36, in the aortic tissue, with a greater increase in Pik3c2a+/– 
mice compared with wild-type mice (P < 0.05, Fig. 6i). Immunostaining using Mac3-
specific antibody, a macrophage marker, revealed a greater number of infiltrating 
macrophages, which are the major source of MMPs, mainly in the adventitia of 




This study shows that the class II PI3K-C2α in EC has indispensable roles in sprouting 
angiogenesis and subsequent mural cell recruitment, and in maintaining vascular barrier 
integrity in quiescent vessels. Deficient C2α actions result in impaired angiogenesis and 
pathological vascular hyperpermeability with vascular damage. At the cellular level, C2α 
is essential for EC migration, proliferation/survival and VE-cadherin assembly at the 
intercellular junction. The actions of C2α are mediated by its regulatory effects on the 
intracellular vesicular transport, i.e. the delivery and recycling of membrane molecules, 
and cell signaling, which likely occurs on endosomes (Supplementary Fig. 20). These 
C2α actions underlie its roles in angiogenesis and barrier integrity. The actions of C2α 
and class I PI3Ks in EC are distinct in that, different from C2α, class I PI3Ks exert a 
great impact on Akt stimulation and cell proliferation and are not involved in vesicular 
trafficking including VE-cadherin transfer or VE-cadherin assembly at the cell-cell 
junction10-13. Therefore, these observations reveal novel biological activities of C2α and 
underscore broader roles for PI3K family members in vascular physiology and 
pathophysiology. 
In contrast to class I PI3Ks that generate PtdIns(3,4,5)P3, the major product of class II 
and III PI3Ks is PtdIns(3)P, which is mainly accumulated in endosomes16-18,20-25. 
Consistent with this, C2α in EC was localized in endosomes and TGN, which are 
organelles responsible for processing, sorting and packaging proteins into distinct carriers 
for transport to their final destinations. Another class II PI3K-C2β and class III Vps34 are 
also localized primarily in the clathrin-coated or endocytic compartment38,39. Localized 
production of PtdIns(3)P together with Rab GTPases including Rab5 on the endocytic 
membrane causes the recruitment of proteins such as early endosome antigen 1 (EEA1) 
and Rabenosyn-5 to facilitate dynamic formation of endocytic membranous structures for 
uptake, packaging and sorting30,39. In EC, C2α is an PI3K isoform that is largely 
responsible for PtdIns(3)P accumulation on endosomes and seems to have a functionally 
distinct role from those of C2β and Vps34: depletion of C2α but not Vps34 severely 
impairs trafficking of 2×FYVE+-vesicles. Among others, C2α deficiency impedes 
delivery of VE-cadherin to intercellular junctions and its normal assembly. C2α is also 
necessary for receptor internalization. Thus, C2α is likely located in a different endocytic 
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compartment from C2β and Vps34 in EC or C2α activity is regulated differentially from 
that of C2β and Vps3418,23,40. Thereby, C2α serves specialized functions in vesicular 
trafficking in EC. 
Our data also show that C2α is involved in cell signaling. Endocytosis has long been 
recognized as a mechanism for terminating signaling by internalizing and degrading cell 
surface receptors39. Besides this classical role of endocytosis, recent studies32,42,43 
demonstrate that endosomes serve as platforms to assemble membrane receptors and their 
downstream signaling molecules and to generate spacially localized signals. In EC, 
activation of RhoA, Rac1 and Rap1 but not Akt or ERK by VEGF-A and FGF2 is 
dependent on C2α to varied extents, indicating that the generation of particular 
intracellular signals requires C2α. Our study shows that C2α is essential for the 
internalization of activated VEGFR2 and endosomal RhoA activation. Consistent with 
the role of endosomes in receptor signaling, blockade of endocytosis suppressed VEGF-
A-induced RhoA activation. Localized activation of RhoA was recently shown to be 
necessary for proper assembly of VE-cadherins at the intercellular junctions and a 
barrier-protective activity 44–46, although evidence for the opposite barrier-disruptive 
activity of RhoA has accumulated4,47. Our data indicate that C2α-dependent RhoA 
activity on endosomes is crucial for delivery and assembly of VE-cadherin at the cell 
boundary and cell-cell contact formation. The Rho-guanine nucleotide exchange factor 
(Rho-GEF), which is responsible for VEGF-induced endosomal RhoA activation in EC, 
and the molecular mechanisms for recruitment and activation of the Rho-GEF remain to 
be determined.  Rap1 and Rac1 are also implicated in strengthening the VE-cadherin-
mediated intercellular junction4,48,49. 
The present study suggests that the effects of C2α on endocytic trafficking play a 
pivotal role in EC migration, proliferation/survival and vascular morphogenesis through 
endosomal transport and signaling. For example, Rho and Rac are activated at the rear 
and front ends, respectively, in migrating cells to drive machineries to retract the rear 
portion of the cell body and to extend protrusions forward. During cell migration, there is 
assembly and disassembly of focal adhesions, which is carried out by endocytic and 
recycling vesicular movements49,50. Rho GTPases are involved in the formation of focal 
adhesions. Focal adhesions also serve as signaling machinery to generate cell survival 
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signals through mechanisms involving integrin ligation. Polarization of the EC 
monolayer in the vascular wall also depends on membrane trafficking51. Endosomes 
could be involved in these processes through both serving as a platform for the activation 
of Rho GTPases and recruiting Rho GTPases to specific sites within cells45. Taken 
together, our observations strongly suggest that C2α fulfills a role in angiogenesis and 
vascular integrity through regulating vesicular trafficking. 
In adult mice, C2α expression is generally diminished compared with that in embryos, 
but is still dominant in the vascular endothelium among other tissues19. Our data show 
that C2α is essential for maintaining barrier integrity in quiescent vessels as evidenced by 
its protective role against VEGF-A-induced hyperpermeability. In anaphylaxis, a 50% 
reduction in C2α expression markedly increased mortality. In chronic vascular injury 
induced by Ang II infusion, disruption of the vascular wall occurs, leading to fatal 
dissecting aneurysm formation. C2α also likely plays a role in maintaining EC survival 
and vascular stability in quiescent vessels. Collectively, our data are consistent with the 
notion that a normal level of C2α expression is essential for the maintenance of vascular 
integrity in quiescent vasculature as well as in neovesssel formation. These observations 
point to the possibility that C2α may become a new therapeutic target for vascular 




Methods and associated references are available in the online version of the paper at 
http://www.nature.com/naturemedicine/. 
Note: Supplementary information is available on the Nature Medicine website. 
ACKNOWLEDGMENTS 
We thank K. Mitsumori for comments on histological study. We thank N. Mochizuki and 
K. Ando for assistance of the FRET imaging analysis. We thank N. Furusawa, K. 
Sunagawa and E. Kaneko for assistance with live-cell imaging using a Yokogawa 
confocal microscope system. We also thank Y. Ohta and T. Murakawa for technical 
assistance and T. Hirose for administrative assistance. C2α cDNA was obtained from J. 
Domin (Imperial College London). GFP-2×FYVE and mRFP-2×FYVE expression 
vectors were obtained from H. Stenmark (Oslo University Hospital) and Y. Ohsumi 
15 
 
(Tokyo Institute of Technology), respectively. VE-cadherin-GFP expression vector were 
obtained from N. Mochizuki (National Cerebral and Cardiovascular Center). pRaichu-
RhoA probe was obtained from M. Matsuda (Kyoto University) GFP-RhoAN19 and GFP-
RhoAV14 expression vectors were obtained from F. Valderrama (King’s College London). 
This work was supported in part by grants-in-aid from the Japanese Ministry of 
Education, Culture, Sports, Science and Technology, the Japan Society for the Promotion 
of Science (to K.Yoshioka, N.T., O.Y. and Y.T.), the Honjin Foundation, the Mitsubishi 




K.Yoshioka the designed the experiments, performed characterization of developmental 
and retinal angiogenesis of the conditional KO mice and most of the in vitro studies, and 
analyzed the data with assistance from N.Takuwa, Y.O., W.D., S.A., H.M., C.N., M.U., 
K.B., and O.M.  K.A. and T.S. analyzed the cellular content of phosphoinositides. 
K.Yoshida performed in vivo angiogenenesis experiments with K.Yoshioka, tumor 
implantation and aneurysm experiments, and interpreted the results. H.C. performed the 
anaphylaxis experiments. D.W. performed the in vivo permeability study. X.Q. and Y.O. 
performed and interpreted the results of the ischemic angiogenesis model. T.W. and S.I. 
performed and interpreted the results of electron microscopy. K.S., M.A., N. Takuwa, 
R.J.S., H.O., and R.H.A. generated mouse mutants. K.Yoshioka and Y.T. planned and 
supervised the experiments, arranged the figures and wrote the manuscript. M.A. and N. 
Takuwa participated in writing the manuscript (M.A.: part of the Methods, N. Takuwa: 
the Abstract, Introduction and Results in the paper). 
 
 
COMPETING FINANCIAL INTERESTS 
 




1. Adams, R.H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. 
Nature Rev. Mol. Cell Biol. 11, 329–341 (2010). 
2. Coultas, L. et al. Endothelial cells and VEGF in vascular development. Nature 438, 937–945 
(2005). 
3. Andrae, J. et al. Role of platelet-derived growth factor in physiology and medicine. Genes 
Dev. 22, 1276–1312 (2008). 
4. Mehta, D. & Malik, A.B. Signaling mechanisms regulating endothelial permeability. Physiol. 
Rev. 86, 279–367 (2006). 
5. Dejana, E., Tournier-Lasserve, E. & Weinstein B.M. The control of vascular integrity by 
endothelial cell junctions: Molecular basis and pathological implications. Dev. Cell 16, 209–
221 (2009). 
6. Yoshimura, K. et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-
terminal kinase. Nature Med. 11, 1330–1338 (2005). 
7. Satoh, K. et al. Cyclophilin A enhances vascular oxidative stress and the development of 
angiotensin II-induced aortic aneurysms. Nature Med. 15, 649–656 (2007). 
8. Ferrara, N. & Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 438, 967–974 
(2005). 
9. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005). 
10. Engelman, J. A. et al. The evolution of phosphatidylinositol 3-kinases as regulator of growth 
and metabolism. Nature Rev. Genet. 7, 606–619 (2006). 
11. Takenawa, T. & Suetsugu, S. The WASP-WAVE protein network: connecting the membrane 
to the cytoskeleton. Nature Rev. Mol. Cell Biol. 8, 37–48 (2007). 
12. Vanhaesebroeck, B. et al. The emerging mechanisms of isoform-specific PI3K signaling. 
Nature Rev. Mol. Cell Biol. 11, 329–341 (2010). 
13. Graupera, M. et al. Angiogenesis selectively requires the p110α isoform of PI3K to control 
endothelial cell migration. Nature 453, 662–666 (2008). 
14. Yuan, T. & Cantley, L.C. PI3K pathway alterations in cancer: variations on a theme. 
Oncogene 27, 5497–5510 (2008). 
15. Funderburk, S.F., et al. The Beclin 1-Vps34 complex at the crossroads of autophagy and 
beyond. Trends. Cell Biol. 20, 355–362 (2010). 
16. Falasca, M. et al. The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. 
Chem. 282, 28226–28236 (2007). 
17. Linassier, C. et al. Molecular cloning and biochemical characterization of a Drosophila 
phosphatidylinositol-specific phosphoinositide 3-kinase. Biochem. J. 321, 849–856 (1998). 
18. Domin, J. et al. The class II phosphoinositide 3-kinase PI3K-C2α is concentrated in the 
trans-Golgi network and present in clathrin-coated vesicles. J. Biol. Chem. 275, 11943–
11950 (2000). 
19. El Sheikh, S.S., et al. Topographical expression of class IA and class II phosphoinositide 3-
kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin. 
Pathol. 3, 1–14 (2003). 
20. Yoshioka, K. et al. Ca2+-induced, Rho- and Rho kinase-dependent regulation of myosin 
phosphatase and contraction in isolated vascular smooth muscle cells. Mol. Pharmacol. 71, 
912–920 (2007). 
21. Traer, C.J. et al. Are class II phosphoinositide 3-kinases potential targets for anticancer 
therapies? Bull Cancer 93, E53–8 (2006). 
17 
 
22. Gaidarov, I. et al. Individual phosphoinositide 3-kinase C2α domain activities independently 
regulate clathrin function. J. Biol. Chem. 280, 40766–40772 (2005). 
23. Falasca, M. & Maffucci, T. Role of class II phosphoinositide 3-kinase in cell signalling. 
Biochem. Society Transactions 35, 211–214 (2006). 
24. Wang, Y. et al. Class II phosphoinositide 3-kinase alfa-isoform regulates Rho, myosin 
phosphatase and contraction in vascular smooth muscle. Biochem J. 394, 581–592 (2006). 
25. Harris, D. et al. Requirement for class II phosphoinositide 3-kinase C2α in maintenance of 
glomerular structure and function. Mol. Cell. Biol. 31, 63–80 (2011). 
26. Moses, K.A.  et al. Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter 
mice. Genesis. 31, 176–180 (2001). 
27. Kisanuki Y.Y. et al. Tie2-Cre transgenic mice: A new model for endothelial cell-lineage 
analysis in vivo. Dev.Biol. 230, 230–242 (2001). 
28. Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. 
Nature 465, 483–486 (2010). 
29. Pannekoek, W. et al. Cell-cell junction formation: The role of Rap1 and Rap1 guanine 
nucleotide exchange factors. Biochim. Biophys. Acta, 1788, 790–796 (2009). 
30. Gillooly, D. J. et al. Localization of phosphatidylinositol 3-phosphate in yeast and mammalian 
cells. EMBO J. 19, 4577–4588 (2000). 
31. Lindmo, K. & Stenmark, H. Regulation of membrane traffic by phosphoinositide 3-kinase. J. 
Cell Sci. 119, 605–614 (2006). 
32. Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and membrane dynamics. 
Nature 443, 651–657 (2006). 
33. Macia, E. et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839–850 
(2006) 
34. Cauwels, A. et al. Anaphylactic shock depends on PI3K and eNOS-derived NO. J. Clin. 
Invest. 116, 2244–2251 (2006) 
35. Daugherty, A. & Cassis L.A. Mouse models of abdominal aortic aneurysms. Arterioscler 
Thromb Vasc Biol. 24, 429–434 (2004). 
36. Di Gennaro, A. et al. Increased expression of leukotriene C4 synthase and predominant 
formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. PNAS 107, 21093–
21097 (2010). 
37. Wheeler, M. & Domin, J. The N-terminus of phosphoinositide 3-kinase-C2β regulates lipid 
kinase activity and binding to clathrin. J. Cell. Physiol. 206, 586–593 (2006). 
38. Simonsen, A. & Tooze, S.A. Coordination of membrane events during autophagy by multiple 
class III PI3-kinase complexes. J. Cell Biol. 186, 773–782 (2009). 
39. Caswell, P. & Norman, J. Endocytic transport of integrins during cell migration and invasion. 
Trends Cell Biol. 18, 257–263 (2008). 
40. Johnson, E.E. et al. Gene silencing reveals a specific function of hVps34 
phosphatidylinositol 3-kinase in late versus early endosomes. J. Cell Sci. 119, 1219–1232 
(2005). 
41. Doherty, G.J. & McMahon, H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 31.1–
31.46 (2009) 
42. Zoncu, R. et al. A phosphoinositide switch controls the maturation and signaling properties of 
APPL endosomes. Cell 136, 1110–1121 (2009). 
43. Palamidessi, A. et al. Endocytic trafficking of Rac is required for the spatial restriction of 
signaling in cell migration. Cell 134, 135–147 (2008). 
18 
 
44. van Nieuw Amerongen, G. P. et al. Involvement of Rho kinase in endothelial barrier 
maintenance. Arterioscler. Thromb. Vasc. Biol. 27, 2332–2339 (2007). 
45. Yamada, S. & Nelson, W.J. Localized zones of Rho and Rac activities drive initiation and 
expansion of epithelial cell-cell adhesion. J. Cell. Biol. 178, 517–527 (2007). 
46. Harris, T. J. C. & Tepass, U. Adherens junctions: from molecules to morphogenesis. Nature 
Rev. Mol. Cell Biol. 11, 502–514 (2010). 
47. Abraham, S. et al. VE-cadherin-mediated cell-cell interaction suppresses sprouting via 
signaling to MLC2 phosphorylation. Curr. Biol. 19, 668–674 (2009). 
48. Noda, K. et al. Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to 
circumferential actin bundles through α- and β-catenins in cyclic AMP-Epac-Rap1 signal-
activated endothelial cells. Mol. Biol. Cell 21, 584–596 (2010). 
49. Webb, S.G., Parsons, J.T. & Horwits, A.F. Adhesion assembly, disassembly and turnover in 
migrating cells – over and over and over again. Nat Cell Biol. 4, E97–100 (2002). 
50. Mitra, S.K., Hanson, D.A. & Schlaepfer, D.D. Focal adhesion kinase: In command and 
control of cell motility. Nat Rev. Cell Biol. 6, 56–68 (2005). 





Mice.  All mice used in this study were bred and maintained at Institute for Experimental Animals, 
Advanced Science Research Center, Kanazawa University, under specific pathogen-free conditions. All 
procedures were conducted in accordance with Fundamental Guidelines for Proper Conduct of Animal 
Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry 
of Education, Culture, Sports, Science and Technology of Japan approved by the Committee on Animal 
Experimentation of Kanazawa University. 
A gene-targeting strategy to generate global Pik3c2a-null mice is described in Supplementary 
Methods. Four lines of Cre-mice, Tie2Cre27, SM22αCre (B6.129S6-Taglntm2(cre)Yec/J, Jackson Lab.), Nkx2-
5Cre26 and tamoxifen-inducible EC-specific Cdh5(PAC)-CreERT2 (ref.28,52,53); Pik3c2a flox/+ mice and 
Pik3c2aflox/flox mice were bred to generatePik3c2aΔEC (Pik3c2aflox/flox;Tie2Cre), Pik3c2aΔSMC 
(Pik3c2aflox/flox;SM22αCre), Pik3c2aΔMC (Pik3c2aflox/flox;Nkx2-5Cre) and Pik3c2aiΔEC 
(Pik3c2aflox/flox;Cdh5(PAC)-CreERT2) mice, respectively. Cre-negative littermates were used as control 
mice. To verify the efficiency of Cre recombination, Cre mice were mated with animals of the Cre reporter 
transgenic line ROSA26-LacZ (B6.129S4-Gt(ROSA)26Sortm1Sor/J, Jackson Lab.). All animals had a 
C57BL/6J genetic background. Gene inactivation in pups was triggered by intraperitoneal (i.p.) injection of 
50 µl of tamoxifen solution (Sigma, T5648; 10 mg ml-1 corn oil) once at P3 or P6. The phenotypes of 
mutant mice were analyzed at P6 or P9, as indicated. For adult mice, tamoxifen was administered by 
intraperitoneal (i.p.) injection of 100 µl of a 10 mg ml-1 tamoxifen stock solution (= 1 mg per injection) a 
total of 7 times, every second day. 
 
Cell culture and siRNA knockdown.  Mouse embryonic fibroblasts (MEF) and aortic smooth muscle  
cells (MASM) were isolated from Pik3c2aflox/flox mice and used for in vitro assay. Pik3c2aflox/flox MEF and 
MASM cells were cultured in Dulbecco’s modified minimal essential medium (DMEM) (WAKO) and 
advanced DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS), respectively, up to 70% 
conluency and then were infected with adnovirus-encoding cre recombinase (AdCre) in the absence of 
serum. Infection with adnovirus-encoding LacZ (AdLacZ) was used as control. After 1 h, culture medium 
containing 10% FBS was added, and cells were allowed to recover for the next 48 h. Greater than 90% C2α 
deletion was confimed by western blotting.  HUVEC (passage 2–4) (Lonza) were grown in endothelial 
basal medium supplemented with 2% FBS and growth factor supplements cocktail (complete growth 
medium) (EBM2TM; Lonza #CC-3162). HUVEC were transfected with 20 nM of short interfering RNA 
(siRNA) using Lipofectamine 2000 (Invitrogen) in OptiMEM (2 µl ml-1, Gibco) according to the 
manufacturer’s instructions. After 4 h, the media were replaced with complete growth medium. The cells 
were cultured for further 48–72 h before processing for immunofluorescence staining and other assays. 




Whole-mount staining and immunofluorescent staining. For tissue immunohistochemistry, 4% 
paraformaldehyde (PFA)-fixed, paraffin embedded tissue sections were stained using standard methods. 
The frozen sections were prepared by cryoprotecting fixed tissue in 20% sucrose for overnight at 4 °C, 
snap-frozen in Optimal Cutting Temperature (OCT) compound (Tissue Tek) and sectioning with a Sakura 
Tissue-Tek Cryo3 Cryostat. Sections (7–30 µm) were washed in Ca2+- and Mg2+-free Dulbecco’s phosphate 
buffered saline (PBS) and incubated with primary antibodies diluted in the antibody dilution solution (Can 
Get Signal, Toyobo) overnight at 4 °C or for 2 h at room temperature. Sections were then washed in PBS 
with 0.1% Triton X-100 and incubated with Alexa Flour-conjugated secondary antibodies for 1 h at room 
temperature. Antibodies used in this report were listed in Antibodies and Reagents in Supplementary 
Methods. Whole-mount immunostaining of CD31 was performed using the labeled streptavidin biotin 
method as described previously54. Alternatively, skin from the embryo head region, flat-mount retinas from 
postnatal mice (P6 or P9), and en face preparations of mouse aorta were used for whole-mount 
immunostaining, as described previously55 with minor modification. PFA-fixed tissues were permeabilized 
with methanol when necessary. Samples were incubated in blocking buffer (1% BSA, 0.3% Triton X-100 
in PBS) for 2 h, washed three times in Pblec buffer (1% Triton X-100, 1 mM CaCl2, 1 mM MgCl2, 1 mM 
MnCl2 in PBS, pH 6.8), and incubated overnight with biotinylated isolectin B4 (Vector B-1205, 1:50) and 
CD31- (1:100), FITC-conjugated SMα-actin- (1:100), NG2- (1:100) and biotinylated VE-cadherin- (1:100) 
specific antibodies diluted in Pblec buffer at 4 °C with gentle rocking. For secondary detection, Alexa 
Fluor-594-conjugated streptavidin (1:200) or Alexa Fluor-488-conjugated species-specific IgG antibodies 
(1:500) diluted in blocking buffer were applied overnight at 4 °C. 
For immunofluorescent cell staining, cells were cultured on collagen-I (Type I-P, Nitta gelatin)-coated 
glass-bottom dishes or Lab-Tek chamber slides in a complete growth medium (see below) and allowed to 
adhere overnight. The cells were rinsed with pre-warmed Ca2+- and Mg2+-containing PBS once and fixed in 
pre-warmed 4% fresh PFA / PBS for 15 min, washed in PBS, and then permeabilized in 0.2% Triton X-100 
in PBS for 5 min when necessary. The cells were incubated with blocking reagent (DAKO #X0909) for 10 
min to inhibit nonspecific protein binding. For some experiments, the cells were alternatively fixed and 
permeabilized by immersion in acetone or methanol at –20 °C for 10 min. After blocking, cells were 
incubated with primary antibodies for 2 h at room temperature or overnight at 4 °C or with Alexa594-
conjugated phalloidin (Molecular Probe #A-12381, 1:200). Then the cells were incubated for 1 h with goat 
AlexaFlour 488 or 594-conjugated secondary antibodies (1:1000) in PBS.  In immunostaining of active 
GTP-RhoA,  HUVEC were serum-starved in M199 medium including 0.5% fatty acid-free bovine serum 
albumin (BSA) for overnight and were stimulated with VEGF-A165 (50 ng ml-1) or EBM2 complete growth 
medium for 30 min and underwent double immunofluorescent staining by using active RhoA-specific 
antibody (for GTP-RhoA, NewEast Biosciences, #26904, 1:400), which is produced against GTPγS-bound 
RhoA antigen, and Alexa594-conjugated phalloidin (for F-actin) as described in above method. Where 
appropriate, cells were counterstained with 4’, 6-diamidino-2-phenyliindole (DAPI, Molecular Probe, 300 
nM) for 5 min. The cells were mounted on Prolong Gold (Molecular Probe) as an anti-photobleaching 
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agent and examined using an inverted fluorescence microscope (Olympus IX70) under a PlanApo 
×40/NA0.95 objective, a confocal laser-scanning microscope (Zeiss Axiovert 200M with LSM5 Pascal) 
equipped with a ×63/NA1.4 PlanApo oil-immersion objective. For quantification of the amount of positive 
pixels, the positive area in stained images in each frame was calculated using Image J software. 
Quantifications represent at least three independent experiments with > 50 cells per experiment. Adobe 
Photoshop was used to adjust image levels and process image overlays. 
 
Detection of LacZ by X-gal staining and immunostaining. For 5-bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal) staining, whole embryos or tissues were dissected from E16.5–E18.5 embryos, fixed in 
X-gal fixative solution (0.25% glutaraldehyde, 5 mM EGTA, 2 mM MgCl2, in PBS) at room temperature 
for 30 min, and then washed in wash buffer (2 mM MgCl2, 0.02% NP-40 in PBS) for 10 min (3 times). 
Samples were stained in X-gal staining solution (1 mg ml-1 X-gal, 5 mM potassium ferricyanide, 5 mM 
potassium ferrocyanide in wash buffer) at 37 °C until desired staining level had been achieved. 
Alternatively, LacZ-specific antibody (MP Cappel #59761, 1:400) was used for multicolor-
immunofluorescence staining, as described previously56. Samples were imaged on a Leica MZ16F 
stereomicroscope (Whole–mount tissue) or a Zeiss Axiovert 200M microscopy with LSM5 Pascal confocal 
laser-scanning unit using Image Browser software (Carl Zeiss). 
 
Postnatal retinal angiogenesis model. Eyes were dissected from neonatal mice (mutants or respective 
control littermates) and fixed in 4% PFA for 2 h at room temperature. Flat-mount Isolectin B4 staining of 
retinas was performed as described in Whole-mount staining section. The spreading of the retinal 
vasculature along the vitreal surface was quantified by flat-mounting the retina and analysis using Image-J 
software. The number of branch points and filopodial bursts in arterial zones per unit area in flat-mount 
retina was counted from randomly defined 15–20 microscopic fields from 5–8 retinas per group for each 
genotype. The values were normalized by field size. For labeling of proliferating cells in the retina, 300 µg 
of 5-bromo-2’ deoxyuridine in 100 µl PBS (BrdU, BD) per pup was i.p. injected 2 h before sacrifice. 
Following isolectin-B4 staining, retinas were stained with BrdU-specific antibody (1:100, BD). 
 
Post-ischemic hindlimb angiogenesis model. Male Pik3c2aiΔEC mice and littermates (C57BL/6 
background) were subjected to surgical procedures to achieve unilateral hindlimb ischemia, as described 
previously57. In brief, the femoral artery was exposed and ligated with 8–0 silk, and the whole length of the 
femoral artery was excised. The blood flow of the ischemic (left) and contralateral non-ischemic (right) 
hindlimbs was measured with a laser Doppler blood flow (LDBF) analyzer (Moor Instruments) before and 
after operation. The stored data were analyzed to quantify the mean LDBF per unit two-dimensional area 
on the en-face image of each entire hindlimb in mice in the supine position, which was determined by the 
software provided by the manufacturer (Moor Instruments). For each animal, the values were expressed as 




Tumor angiogenesis model. LLC cells (1 × 106) or B16-BL6 melanoma cells (5 × 105) were 
subcutaneously implanted in the dorsal back of 8–10 week old male Pik3c2aiΔEC and control littermates 
(C57BL/6 background)58. Tumor volumes was calculated by the formula V = (LW2)/2, where L and W 
denote the longer and shorter diameter, respectively. 
 
PAF-induced anaphylaxis model. To trigger anaphylactic shock, 10–12 week old male Pik3c2a+/– or 
littermate wild-type mice received i.v. injection of platelet-activating factor (PAF) (12 or 20 µg kg-1 in 100 
μl saline) via the tail vein, and survival was followed. In separate mice, 15 min after infusion, blood 
samples were obtained from the right ventricle to determine hematocrit. To assess vascular leakage in lung, 
100 µl of a 1% solution of Evans blue dye in saline was injected into the tail vein together with PAF. 15 
min later, mice were perfused with saline via the right ventricle to remove intravascular Evans blue dye. 
The lungs were excised and extracted in 1ml of formamide at 55 °C overnight. Evans blue content was 
determined by the equation; OD620 (corrected) = OD620 – (1.426 × OD740 + 0.03). 
 
Angiotensin II infusion-aortic aneurysm model. An osmotic minipump (Alzet, model 1002) containing 
Ang II (1.0 mg kg-1 per day, Calbiochem) were implanted in the midscapular region in male Pik3c2a 
mutant and WT littermates. Mice were euthanized at day 14 after minipump implantation and aortic tissue 
was removed. The extent of aneurysms was graded according to the following criteria59. Grade 1: 
remodeled tissue in suprarenal region frequently containing thrombus, Grade 2: pronounced bulbous form 
of Grade 1 containing thrombus, Grade 3: multiple aneurysms containing thrombus, Ruptured: ruptured 
aortic aneurysm. Both cryostat and paraffin-embedded aortic sections were used for characterization of 
aneurysmal lesions. Elastin was visualized using Elastica van Gieson (EVG) staining. Fibrosis was 
evaluated using Azan staining. Infiltrating macrophages were detected using Mac3-specific antibody (BD, 
1:400) immunostaining. Miles assay and gelatin zymography were performed as described below. 
 
Live-cell imaging and FRET analysis. Cells that had been transfected with the expression vectors for 
GFP-C2α, GFP/mRFP-2×FYVE, and VE-cadherin-GFP/mRFP were plated on collagen-coated glass-
bottomed dishes (MatTek, #P35G-1.5-20-C) or LabTek chamber slides (Thermo Scientific, #177402), and 
allowed to adhere for 16 h before imaging. Cells on a heated stage (37 °C, Tokai-Hit) were observed under 
a custom confocal microscope based on an inverted IX70 microscope (Olympus) equipped with an 
UPLSAPO ×60/NA1.35-oil or ×40/0.95-oil objective, confocal laser unit (CSU10, Yokogawa), EM-CCD 
digital camera (iXon, Andor) and Light engine (Lumencor, Inc) for 3D time-lapse (4D) confocal imaging at 
a rate of 2 frames per sec. The acquisition and process were controlled by iQ software (Andor). 
For FRET analysis, HUVEC were transfected with the pRaichu-RhoA probe using an Amaxa 
Nucleofector system (Lonza), and imaged using a custom confocal microscope sytem configured with a 
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CFP and YFP filter set (Di01-T445/515/561-13×15×0.5, Semrock). Pseudo-grayscale ratio images were 
generated from images from CFP and FRET channels using Andor iQ software. 
 
Cell proliferation, migration, adhesion, apoptosis and tube-formation assay. Cell proliferation was 
analyzed by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) assay kit (Promega) according to the manufacturer’s instructions. For modified 
Boyden chamber cell migration assay, siRNA-transfected HUVEC (5 × 104 cells per well) resuspended in 
M199 medium (Gibco) containing 0.25% fatty-acid free BSA (Sigma-Aldrich) or adenovirus-infected 
MASM cells (2 × 104 cells per well) resuspended in serum–free DMEM, were placed in the upper chamber  
and allowed to migrate across collagen type I-coated polycarbonate filters (8 µm pore size, Neuro Probe) 
for 6 h toward the lower chamber with or without VEGF-A (0.5–100 ng ml-1) for HUVECs, and with or 
without PDGF-BB (0.1–30 ng ml-1) for MASM. The cells remaining on the upper surface of transwell 
membranes were removed and the cells that had migrated to the lower surface were methanol-fixed, stained 
with Diff-Quick (Sysmex), and counted in 5 random microscopic fields. To analyze cell adhesion to a 
collagen-covered surface, HUVEC that had been transfected with scrambled (control) or C2α-siRNAs were 
seeded onto 96–well tissue culture plates coated with collagen type I and incubated in the presence of 
VEGF-A (30 ng ml-1) for the indicated time periods. After washing with PBS three times to remove non-
adherent cells, adherent cells were stained with Diff-Quick and quantified in triplicates with a microplate 
reader (Bio-Rad). For apoptosis assay, cells were immunostained with cleaved caspase-3-specific antibody 
according to the manufacturer’s instructions (Cell Signaling). For tube formation assay, siRNA-transfected 
HUVEC (2.5 × 104 cells) in EBM2 containing 2% FBS with or without supplements were seeded onto 200 
µl of growth factor-reduced Matrigel in a 24–well plate in the absence or presence of VEGF-A (30 ng ml-1) 
and incubated for 12–16 h. Tube formation was quantified after 12–16 h by measuring the cumulative tube 
length and branching points number in five random microscopic fields by using ImageJ (NIH).  
 
Pull-down assay of small G-protein activity. The pull-down assays for GTP-bound RhoA, Rac1 and 
Rap1were performed as described previously58. In brief, confluent HUVEC were stimulated and lysed with 
either the Rho extraction buffer (50 mM Tris-HCl pH7.5, 500 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol, protease/phosphatase inhibitor cocktail (Roche)), the 
Rac extraction buffer (50 mM Tris-HCl pH7.5, 500 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS, 10% glycerol, protease inhibitor cocktail), or the Rap extraction buffer 
(20 mM Tris-HCl pH7.5, 100 mM NaCl, 10 mM MgCl2, 1% NP-40, 1 mM EGTA, protease inhibitor 
cocktail). The lysates were cleared by centrifugation and the resultant supernatants were incubated for 60 
min at 4 °C with glutathione-Sepharose 4B beads coupled to the Rho binding domain of Rhotekin for 
RhoA, PAK1-CRIB domain for Rac1, and Rap binding domain of Ral-GDI for Rap1. The beads were 
washed and bound proteins were solubilized by the addition of 30 µl of SDS-PAGE 2 × Laemmli’s loading 
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buffer, followed by separation on 15% SDS-PAGE gels and western blotting with RhoA (1:1,000)-, Rac1 
(1:2,000)- and Rap1 (1:1,000)-specific antibodies, respectively. 
 
In vitro transwel and in vivo Miles permeability assay. C2α- or scrambled siRNA-transfected HUVEC 
were seeded onto collagen-coated transwells with 0.4 µm pore–size (Costar) and allowed to form a 
monolayer. Permeability was stimulated with VEGF-A165 (50 ng ml-1) or thrombin (0.5 U ml-1) for 30 min, 
followed by addition of FITC-dextran (a final concentration of 1 mg ml-1) (Mr = 42 kDa, Sigma-Aldrich) 
into the top chambers and then incubation for additional 30 min. The amount of FITC-dextran in the 
bottom chambers was determined by fluorometric analysis. 
For in vivo permeability assay, 1.0% Evans blue dye in saline (100 µl) was i.v. injected into the tail 
vein of Pik3c2a+/+ and Pik3c2a+/– mice, and allowed to circulate for 20 min. Recombinant human VEGF-
A165 (100 ng ml-1, 100 µl, PeproTech) or PBS was injected intradermally into the pre-shaved back skin. 
After 20 min, the mice were sacrificed, and the area of skin that included the entire injection site was 
removed. For Ang II-infusion model, 100 µl of a 1% solution of Evans blue dye in saline was injected into 
the tail vein of male Pik3c2a+/– or Pik3c2a+/+ littermatee that received Ang II infusion for 14 days 
beforehand (1.0 mg kg-1 per day). 30 min later, mice were perfused with saline via the right ventricle to 
remove intravascular Evans blue dye, and heart and aorta tissues were excised. Evans blue dye was 
extracted from the tissues by incubation with formamide overnight at 55 °C, and Evans blue content was 
determined spectrophotometrically as described above. 
 
Metabolic cell labeling, lipid extraction and phosphoinositide measurement. The amounts of cellular 
phosphoinositides were determined as described previously60. In brief, MEF cells were labeled for 48 h 
with 10 µCi ml-1 [3H]-myo-inositol (Amersham Biosciences) in inositol-free DMEM containing 10% FBS. 
Labeling was quenched and lipids were extracted as described60. Dried lipids were deacylated and analyzed 
by HPLC using a Partisphere SAX column (Whatman). Radioactivity was measured in 0.5 ml fractions 
using a liquid scintillation counter.  
 
Statistical analysis. Unless otherwise noted, data are presented as means ± SEM and were analyzed using 
Prism 5 software (GraphPad Software Inc). Paired data were compared by two-tailed Student’s t-test or 
Mann-Whitney nonparametric U-test. Comparisons between multiple groups were analyzed by one- or two-
way ANOVA with a subsequent post-hoc test. Results with P < 0.05 were considered statistically 
significant. The presented data represent at least three independent experiments. 
 
Additional methods. Detailed methodology is described in the online Supplementary Methods. 
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Figure 1  Endothelial C2α is necessary for developmental angiogenesis. 
(a) Whole-mount CD31-specific immunohistochemical staining of the 
vasculatures in E11.5 wild-type and global Pik3c2a–/– embryos. The magnified 
views show the brain (asterisk (left bottom)), dorsal aorta (red arrowhead (right 
bottom)) and intersomitic vessels (yellow arrowhead (right bottom)) in Pik3c2a–/– 
embryo. Scale bar, 2 mm. (b) αSMA-specific imunohistochemical staining in 
cross-sections of dorsal aorta and heart from E11.5 wild-type and Pik3c2a–/– 
embryos. Scale bar, 100 µm. (c) Left three panels (top and bottom): gross views 
and HE staining of skin sections of E15.5 control and homozygous EC-specific 
C2α-deletion mutant (Pik3c2aΔEC) embryos (black arrowheads, normal dermal 
vessels;  red arrowheads, dilated vessels and hemorrhage). Right three panels 
(top and bottom): whole-mount CD31 (red)- and αSMA (green)-specific, and VE-
cadherin (red)- and NG2 (green)-specific double immunofluorescent staining of 
the skin sections in E15.5 control and Pik3c2aΔEC embryos (white arrowheads in 
CD31 and αSMA staining, loosely attached αSMA+ SMCs; yellow and white 
arrowheads in VE-cadherin and NG2 staining, loosely attached and detached 
NG2+-pericytes, respectively). Arteriole (a) and venule (v) are indicated. Scale 
bar, 100 µm. (d) Quantified data of vessel area and branch points. n = 6 mice per 
group. (e) CD31- and β-galactosidase (βGal)-specific double immunofluorescent 
staining of brain sections in E15.5 control (Pik3c2aflox/flox;Rosa26R) and EC-
specific C2α-deleted (Pik3c2aflox/flox;Tie2Cre; Rosa26R (Pik3c2aΔEC;Rosa26R)) 
embryos. Scale bar, 50 µm.  
 
Figure 2  C2α is required for postnatal retinal angiogenesis. 
(a) Western blot analysis of C2α, p110α, C2β and Vps34 proteins in mouse lung 
EC (MLEC) and aortic smooth muscle cells (MASM) from 4–week old control 
(Pik3c2aflox/flox) and Pik3c2aiΔEC mice with or without tamoxifen (Txf) 
administration as described in (b). (b) Diagram of experiments during early 
formation of retinal vasculature (P3–P6) in Pik3c2aiΔEC. Flat-mount Isolectin-B4 
(IsoB4) staining of retinas from control (top; Pik3c2aflox/flox) and tamoxifen (i.p. at 
P3)-inducible EC-specific C2α deletion mutant mice (bottom; Pik3c2aiΔEC) at P6. 
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Yellow dots and arrowheads indicate filopodia and apoptotic cells, respectively. 
Scale bar, 100 µm. Vessel area and numbers of tip cells and filopodia per field 
were quantified (right). n = 6–11 mice per group. (c) Diagram of experiments 
during late development of retinal vasculature (P6–P9) in Pik3c2aiΔEC. The 
images of the sections at different levels in flat-mount IsoB4 staining of retinas 
from control and Pik3c2aiΔEC mice at P9 (left). Maximum intensity projection 
(MIP) images and x–z view of the retinal vasculature showing perpendicular 
sprouting (arrowheads) at P9 (right). Scale bar, 50 µm. 
 
Figure 3  Tube-formation, cell migration and RhoA activation are impaired 
in C2α-depleted HUVEC. 
(a) Effects of siRNA-mediated PI3K knockdown on VEGF-A (20 ng ml-1)-induced 
tube formation in serum/growth factor supplement-free medium. Scale bar, 200 
µm. Quantification of total tube length (right).  n = 3. (b) Effects of C2α 
knockdown or deletion on VEGF-A-directed HUVEC migration and PDGF-BB-
directed MASM migration. n = 3. (c) Effects of C2α depletion on VEGF-A-
induced signaling. (d) Quantification of VEGF-A-induced phosphorylation of 
MYPT1. (e) Effects of C2α knockdown on VEGF-A-induced RhoA activation in 
HUVEC. The protein expression of C2α and C2β are shown on the top. (f) 
Quantified data of the results in (e). Data in (d) and (f) are shown as relative 
values of normalized band intensities. n = 3. 
 
Figure 4 Endosomal transport and assembly of VE-cadherin and 
endosomal RhoA activation are impaired in C2α-depleted EC. 
(a) Fluorescent imaging of control HUVEC and C2α-, p110α-, or Vps34-depleted 
HUVEC transfected with mRFP-2xFYVE domain (PtdIns(3)P probe). Scale bar, 
20 µm. Quantification of FYVE+-vesicle numbers per cell is shown (right). n = 11–
14 cells. (b) Fluorescent imaging of VE-cadherin-GFP trafficking in control 
HUVEC, C2α-, p110α-, or Vps34-depleted HUVEC, and LacZ- or RhoAN19-
transfected HUVEC. Yellow arrowheads indicate VE-cadherin+ cell-cell contacts. 
Asterisks point to gaps between HUVEC. Scale bar, 20 µm. See also 
Supplementary movies 4 & 5. (c) Immunoprecipitation and western blot analysis 
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of the association of β-catenin (β-ctn) and p120-catenin (p120-ctn) with VE-
cadherin (VEcad). Quantification of the results (right). n = 3. (d–g) HUVEC were 
transfected with the FRET probe expression vector pRaichu-RhoA. (d) VEGF-A-
induced RhoA activation on the endosomes (yellow arrowheads) and the plasma 
membrane at cell-cell contacts (red arrowheads) in control and C2α-depleted 
HUVEC. (e) VEGF-A-induced RhoA activation in HUVEC co-transfected with the 
expression vectors for Raichu-RhoA and mRFP-2xFYVE. Colocalization of 
endosomal FRET signals (yellow arrowheads (top)) with FYVE+-endosomes 
(white arrowheads (bottom)). Red arrowheads (top) indicate RhoA activation at 
cell-cell contacts. Scale bar, 20 µm. (f) Quantification of endosomal RhoA 
activation in control and C2α-depleted HUVEC. n ≥ 8 cells. (g) Quantification of 
FYVE+-FRET signals in HUVEC. n = 9–22 cells. (h) Immunofluorescent staining 
of VEGFR2 (green) in mRFP-2xFYVE-cotransfected (#), control and C2α-
depleted HUVEC. Quantification of VEGFR2+- and FYVE+-HUVEC (right). n = 8–
20 cells. Scale bar, 20 µm.  
 
Figure 5  Targeted deletion of endothelial C2α decreases post-ischemic and 
tumor angiogenesis. 
(a, b) Post-ischemic hindlimb angiogenesis. Ischemic/non-ischemic limb laser 
Doppler blood flow (LDBF) ratio in male 8–week old control and homozygous EC-
specific C2α deletion mutant (Pik3c2aiΔEC) mice (a). n = 13 mice per group. 
CD31-specific immunofluorescent staining of sections of ischemic hindlimb 
muscle in control and Pik3c2aiΔEC mice (b). Nuclei (blue) were stained with DAPI. 
Scale bar, 100 µm. Quantification of CD31+ microvessel density on day 7 (right). 
n ≥ 20 fields from at least 8 mice. (c) Representative LLC (top) and B16-BL6 
tumors (bottom) in male 10–week old control and Pik3c2aiΔEC mice. Scale bar, 5 
mm. Quantification of tumor weights and volumes (day 14) (right). n ≥ 7 mice per 
group. (d) CD31-specific immunofluorescent staining of LLC tumor sections in 
control and Pik3c2aiΔEC mice. Scale bar, 200 µm. Quantification of CD31+ 
microvessel density (right). n = 7 mice per group. (e) CD31- and NG2-specific 
double immunofluorescent staining of LLC tumor sections in control and 
Pik3c2aiΔEC mice. Yellow and white arrowheads indicate loose attachment and 
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detachment of pericytes, respectively, in Pik3c2aiΔEC mice. Scale bar, 200 µm. 
Nuclei (blue) were stained with DAPI. 
 
Figure 6 C2α disruption causes vascular hyperpermeability and dissecting 
aortic aneurysm formation in vivo. 
(a) Effects of C2α depletion on VEGF-A-induced leak of FITC-dextran across 
HUVEC monolayers. n = 6. (b) Miles assay of VEGF-A-induced Evans blue 
leakage in skin of male 10–week old wild-type and Pik3c2a+/– mice. Quantification 
of Evans blue leakage (right). n = 4–5 mice per group. (c) Survival of male 10–
week old wild-type and Pik3c2a+/– mice after PAF (12 or 20 µg kg-1 i.v.)-induced 
anaphylaxis. Hematocrit after PAF (12 µg kg-1 i.v.) challenge (right). n = 6 mice 
per group.  (d) Extravasation of Evans blue dye in lung after PAF (12 µg kg-1 i.v.) 
challenge. Scale bar, 5 mm. Quantification of Evans blue leakage (right). n = 3–6 
mice per group. (e) Extravasation of Evans blue dye in aorta and heart of male 
10–week old mice receiving chronic infusion of Ang II (1.0 mg kg-1 per day for 2 
weeks). n = 3–5 mice per group. (f) En face confocal microscopic views of VE-
cadherin-specific immunofluorescent staining of aorta from male 10–week old 
mice given Ang II infusion. Scale bar, 50 µm. (g) Aneurysm formation of C2α 
mutant mice given AngII infusion. Gross view of aortic aneurysms (red 
arrowheads) (left top). Scale bar, 1 mm. Incidence of aortic aneurysms in control, 
Pik3c2a+/– and Pik3c2aiΔEC mice (right top). The severity of aneurysms was 
graded as decsribed in the Online Methods section. Azan-stained sections of 
dissecting aortic aneurysm in Pik3c2a+/– mice (bottom). Scale bar, 500 µm.  PL, 
pseudo-lumen; Red arrowhead, adventitia; black arrow, internal elastic lamina 
(IEL); yellow arrow, external elastic lamina (EEL); asterisk, true lumen of aorta. 
(h) Survival of male 8–10 week old mice given Ang II infusion. (i) Matrix 
metalloproteinase (MMP)-2/9 activities are increased in aorta of male 10–week 
old mice given Ang II infusion. Quantification of MMP-2/9 activities. n = 6 mice 
per group. (j) Mac3-specific immunohistochemical staining of the aortic wall of 
male 10–week old mice given Ang II infusion. Red arrowheads, infiltrating 
macrophages; black arrow, internal elastic lamina (IEL); yellow arrow, external 
elastic lamina (EEL). Scale bar, 200 µm. In (c), (g), and (h), mouse numbers are 
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